Ha-ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors.
Ha-ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors.
复制标题
甲状腺癌发生中的 Ha-ras 癌基因（密码子 12）突变：60 例良性和恶性甲状腺肿瘤的分析。
DOI：
--
复制
发表时间：
1995
影响因子：
0.5
通讯作者：
A. Revol
中科院分区：
文献类型：
--
作者：
M. Bouras;P. Parvaz;N. Berger;C. Paulin;A. Revol
原癌基因Ha-ras第12密码子突变在甲状腺癌中常见。然而，它们在这种病理学的启动和发展中的作用仍有待澄清。在这里，我们提出了一个初步的研究，使用60个样本对应于不同类型的癌症。通过PCR（聚合酶链反应）DNA扩增，然后进行RFLP（限制性片段长度多态性）分析，能够检测人类甲状腺腺瘤和癌中Ha-ras癌基因密码子12的点突变。我们的研究结果证实了密码子12 Ha-ras癌基因突变在甲状腺肿瘤中的高频率：腺瘤33%，特别是非典型腺瘤71%，滤泡癌33%，乳头状癌19%（n = 18，7，12，26，分别）。未分化癌中未检测到突变（n = 4）。Ha-ras基因第12密码子点突变可存在于甲状腺良、恶性肿瘤发生发展的各个阶段。它可能是甲状腺肿瘤发生过程的必要组成部分，但并不是唯一的致癌因素。此外，应根据甲状腺癌类型寻找与其他分子异常的相关性。
Protooncogene Ha-ras codon 12 mutations are frequently observed in thyroid cancers. However, their role in the initiation and development of this pathology remains to be clarified. Here we present a preliminary study using 60 samples corresponding to different types of cancer. DNA amplification by PCR (polymerase chain reaction) followed by RFLP (restriction fragment length polymorphism) analysis enabled the detection of a point mutation in codon 12 of the Ha-ras oncogene in human thyroid adenomas and carcinomas. Our results confirm the high frequency of codon 12 Ha-ras oncogene mutation in thyroid tumors: adenomas 33%, with a particularly high rate for atypical adenomas 71%, follicular carcinomas 33%, and papillary carcinomas 19% (n = 18, 7, 12, 26, respectively). No mutation was detected in undifferentiated carcinomas (n = 4). The Ha-ras codon 12 gene point mutation can exist at all stages of development of both benign and malignant thyroid tumors. It may be a necessary part of the thyroid tumorigenesis process, but it is not the only carcinogenic factor. Additionally, the association with other molecular anomalies should be sought depending on the thyroid cancer type.